EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his po...
During September 2025, the number of shares and votes in EQL Pharma AB (“EQL Pharma”) has increased as a result of the exercise of warrants issued pursuant to two warrant programs adopted by the an...
EQL's key product Mellozzan[®] (tablets) has now been launched in the UK by our partner Medice. Medice specialise in ADHD and have previously launched Mellozzan[®] successfully in Germany, among ot...
EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made...
EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally....
